3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
5
Active not recruiting
4
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Breast Neoplasms
9
Neoplasms
7
Multiple Myeloma
7
Prostatic Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
6
Lung Neoplasms
6
Colorectal Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Recurrence
5
Rectal Neoplasms
5
Neoplasm Metastasis
5
Pancreatic Neoplasms
4
Melanoma
4
Leukemia, Myeloid, Acute
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Hodgkin Disease
4
Glioblastoma
4
Urinary Bladder Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Non-Hodgkin
3
Hematologic Neoplasms
3
Head and Neck Neoplasms
3
Colonic Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Hepatocellular
3
Waldenstrom Macroglobulinemia
2
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Interventions
durvalumab
1
Oxaliplatin
1
Leucovorin
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Gallbladder Neoplasms
×
30 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts